Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer

Area of Science:

• Nephrology
• Oncology
• Genitourinary Cancers

Background:

• Non-clear cell renal cell carcinoma (ncRCC) represents a diverse group of kidney tumors with distinct characteristics.
• Currently, no therapies are specifically approved by the Food and Drug Administration (FDA) for ncRCC, classifying it as an orphan disease site.
• ncRCC is often treated with therapies approved for clear cell renal cell carcinoma (ccRCC), despite significant molecular and genetic differences.

Purpose of the Study:

• To review the current state of management for non-clear cell kidney cancers.
• To highlight the clinical relevance and timeliness of addressing ncRCC given recent advancements.
• To explore the impact of molecular and genomic testing on identifying new therapeutic targets for ncRCC.

Main Methods:

• Review of existing clinical trial data and FDA approvals for renal cell carcinoma.
• Analysis of molecular and genomic profiling studies in ncRCC.
• Examination of therapeutic strategies conventionally applied to ccRCC and their applicability to ncRCC.

Main Results:

• Clear cell renal cell carcinoma (ccRCC) has seen numerous recent FDA approvals for new therapies.
• While ncRCC has shown research activity, no specific FDA approvals have been granted.
• Randomized clinical trials specifically for ncRCC remain limited.
• Molecular and tumor genomic testing are revealing specific targets and potential therapies for ncRCC.

Conclusions:

• The management of ncRCC requires specific attention due to its unique biological features and lack of targeted therapies.
• Advancements in genomic testing are paving the way for personalized treatment strategies in ncRCC.
• A dedicated review of ncRCC management is crucial for clinical practice and future research.